首页> 外文期刊>Expert opinion on investigational drugs >Role of melatonin in mood disorders and the antidepressant effects of agomelatine
【24h】

Role of melatonin in mood disorders and the antidepressant effects of agomelatine

机译:褪黑素在情绪障碍中的作用以及阿戈美拉汀的抗抑郁作用

获取原文
获取原文并翻译 | 示例
       

摘要

Introduction: Disturbances of circadian rhythms and sleep play an important role in various types of mood disorders like major depressive disorder (MDD), bipolar depressive disorder (BPD) and seasonal affective disorder (SAD). Malfunctioning of the SCNpinealmelatonin link has been suggested as the main cause for these disorders. As a rhythm-regulating factor and as a hormone involved in the regulation of sleep, melatonin is essential for the control of mood and behavior. Areas covered: Melatonin's involvement in various mood disorders is reviewed based on studies undertaken in patients with MDD, BPD and SAD. The chemistry and metabolism of the newly introduced antidepressant, agomelatine, a MT1/MT2 melatonin receptor agonist and 5-HT2c antagonist in brain areas involved in mood regulation are also discussed. Its clinical role in mood regulation, agomelatine's efficacy, safety and tolerability are also reviewed. Expert opinion: Agomelatine, a melatonergic antidepressant with a rapid onset of action, has been shown effective in various types of mood disorders (e.g., MDD, BPD, SAD). Some studies find it superior to other common antidepressants (SSRIs, SNRIs) that are in clinical use today. Agomelatine's efficacy, good tolerability and safety profile suggest that it may become a preferred antidepressant in the near future.
机译:简介:昼夜节律紊乱和睡眠在各种类型的情绪障碍中起重要作用,例如重度抑郁症(MDD),双相抑郁症(BPD)和季节性情感障碍(SAD)。 SCNpinealmelatonin链接的功能异常被认为是这些疾病的主要原因。褪黑激素作为节律调节因子和参与睡眠调节的激素,对于控制情绪和行为至关重要。涵盖的领域:基于对MDD,BPD和SAD患者进行的研究,评估了褪黑激素与各种情绪障碍的关系。还讨论了新引入的抗抑郁药阿戈美拉汀,MT1 / MT2褪黑素受体激动剂和5-HT2c拮抗剂在涉及情绪调节的大脑区域的化学和代谢。还综述了其在情绪调节,阿戈美拉汀的疗效,安全性和耐受性方面的临床作用。专家意见:Agomelatine是一种褪黑素抗抑郁药,起效迅速,已被证明可有效治疗各种类型的情绪障碍(例如,MDD,BPD,SAD)。一些研究发现,它优于当今临床使用的其他常见抗抑郁药(SSRI,SNRI)。阿戈美拉汀的疗效,良好的耐受性和安全性表明它可能在不久的将来成为首选的抗抑郁药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号